08:00 Thu 10 Sep 2020
ConvaTec Group PLC - Scrip Dividend - Calculation Price

Scrip Dividend - calculation price
On
The "Calculation Price" for the issue of new ordinary shares under the scrip dividend scheme is:
This is equivalent to 1 new share for approximately 142.63 shares held prior to the ex-dividend date of
The Calculation Price is the average of the middle market quotations of a
The latest date for receipt of elections to participate in the scrip dividend scheme for the Interim Dividend is
Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.
TIMETABLE
Key dates in respect of the scrip dividend scheme for the Interim Dividend are:
Ex-dividend Date | |
Record Date | |
Scrip calculation price determined | |
Scrip calculation price available and announced | 10 September 2020 |
Mandate delivery deadline for Shares held in uncertificated form | |
Mandate delivery deadline for Shares held in certificated form | |
Announcement of the total amount of new shares to be issued | 29 September 2020 |
Dividend payment date | |
Dispatch of statement in accordance with section 7 of Scheme | |
Rules and share certificates, CREST accounts credited/updated,
and first day of dealings in New Shares
Enquiries
Analysts and Investors
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
Media
Buchanan: Charles Ryland /
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
# # #
END
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE